Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENALIDOMIDE Cause Upper respiratory tract infection? 1,334 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,334 reports of Upper respiratory tract infection have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 0.4% of all adverse event reports for LENALIDOMIDE.

1,334
Reports of Upper respiratory tract infection with LENALIDOMIDE
0.4%
of all LENALIDOMIDE reports
72
Deaths
411
Hospitalizations

How Dangerous Is Upper respiratory tract infection From LENALIDOMIDE?

Of the 1,334 reports, 72 (5.4%) resulted in death, 411 (30.8%) required hospitalization, and 23 (1.7%) were considered life-threatening.

Is Upper respiratory tract infection Listed in the Official Label?

Yes, Upper respiratory tract infection is listed as a known adverse reaction in the official FDA drug label for LENALIDOMIDE.

What Other Side Effects Does LENALIDOMIDE Cause?

Diarrhoea (27,576) Fatigue (22,956) Death (19,213) Off label use (17,017) Rash (15,794) Pneumonia (14,807) Plasma cell myeloma (14,191) Neuropathy peripheral (10,215) White blood cell count decreased (9,996) Constipation (9,635)

What Other Drugs Cause Upper respiratory tract infection?

ADALIMUMAB (3,306) ETANERCEPT (2,948) TOFACITINIB (1,805) RITUXIMAB (1,713) ABATACEPT (1,623) METHOTREXATE (1,576) TOCILIZUMAB (1,455) APREMILAST (1,437) PREDNISONE (1,354) SECUKINUMAB (1,339)

Which LENALIDOMIDE Alternatives Have Lower Upper respiratory tract infection Risk?

LENALIDOMIDE vs LENIOLISIB LENALIDOMIDE vs LENOGRASTIM LENALIDOMIDE vs LENVATINIB LENALIDOMIDE vs LEPONEX LENALIDOMIDE vs LERCANIDIPINE

Related Pages

LENALIDOMIDE Full Profile All Upper respiratory tract infection Reports All Drugs Causing Upper respiratory tract infection LENALIDOMIDE Demographics